0001628280-26-032146
SEC filingCAMP4's Q1 FY2026 revenue grew 51% to $1.3M, while net loss widened to $18.3M due to a non-cash derivative charge; operating cash burn improved.
Revenue for Q1 FY2026 was $1.3 million, a 50.8% increase from $858,000 in Q1 FY2025. The growth was primarily driven by revenue from the GSK collaboration, which was not present in the prior year period. The prior year included revenue from the BioMarin collaboration.
Research and development expenses increased modestly, driven by personnel-related costs and stock-based compensation. General and administrative expenses also increased, primarily due to professional and consulting fees related to audit and tax costs. The overall operating loss remained stable, indicating disciplined expense management.
Net cash used in operating activities was $11.0 million in Q1 FY2026, compared to $14.3 million in Q1 FY2025, reflecting improved working capital management. Capital expenditures were nil in the current period versus $279,000 in the prior year. Based on the current operating plan, management estimates that cash and cash equivalents as of March 31, 2026 will be sufficient to fund operating expenses and capital expenditure requirements into 2028.
CAMP4 has not generated revenue from product sales and has incurred significant operating losses and negative cash flows from operations. The company's future viability depends on its ability to generate cash from operations or raise additional capital. The company relies on third parties for clinical supply packaging, labeling, storage, and distribution.
CAMP4 remains a pre-revenue clinical-stage company focused on RNA-targeting therapeutics for genetic diseases. The lead candidate, CMP-002 for SYNGAP1, is expected to enter a global Phase 1/2 trial in the second half of 2026, pending regulatory clearance. The company's future viability depends on successful clinical development and eventual regulatory approval, which may take years or may never occur. While the current cash runway into 2028 provides a buffer, the company will need to secure additional funding through equity offerings, debt, or partnerships to support commercialization. Key risks include clinical trial outcomes, regulatory hurdles, and reliance on third-party manufacturers.